Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

By Ani Harutyunyan

Apr 18, 2024

Media Coverage

Using DealForma insights, PharmaShots highlights the Top 20 Biopharma Deal Terminations of 2023, led by the $3.75B Janssen–Arrowhead split. Read it here

DealForma Research

Biopharma Therapeutics and Platforms M&A – 2025 Review

March 9, 2026

Biopharma Therapeutics and Platforms R&D Partnerships – 2025 Review

February 26, 2026

Dermatology M&A – 2024-2025 Review

February 23, 2026

All of this by stage, disease indication, modality, target…

+ 0 k

Licensing Deals

+ 0 k

M&A

+ 0 k

Other Deals

+ 0 k

Funding Rounds

+ 0 k

Company Profiles

+ 0 k

Drug Sales Figures